相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study
Jiong Wu et al.
CANCER RESEARCH (2022)
Pathological response and predictive role of tumour- infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial
Zhenzhen Liu et al.
EUROPEAN JOURNAL OF CANCER (2022)
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
Wei Fang Dai et al.
JAMA ONCOLOGY (2022)
Breast cancer
Sibylle Loibl et al.
LANCET (2021)
Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast Cancer
Jiujun Zhu et al.
FRONTIERS IN ONCOLOGY (2021)
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Sara Pizzamiglio et al.
CLINICAL CANCER RESEARCH (2021)
Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCH-P) in HER2-positive breast cancer: An Indian experience.
Ajay Gogia et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
Jamunarani Veeraraghavan et al.
NPJ BREAST CANCER (2021)
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia The PEONY Phase 3 Randomized Clinical Trial
Zhimin Shao et al.
JAMA ONCOLOGY (2020)
Breast Cancer, Version 3.2020
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pathway-Based Drug Response Prediction Using Similarity Identification in Gene Expression
Seyed Ali Madani Tonekaboni et al.
FRONTIERS IN GENETICS (2020)
Neoadjuvant docetaxel with or without carboplatin plus dual HER2 blockade for HER2-positive breast cancer: a retrospective multi-center Chinese study
Minhao Lv et al.
GLAND SURGERY (2020)
Dual HER2 Blockade in Neoadjuvant Treatment of HER2+Breast Cancer: A Meta-Analysis and Review
Chaokun Wang et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2020)
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel plus trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
Samuel A. Jacobs et al.
BREAST CANCER RESEARCH (2019)
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Jiani Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Tejal A. Patel et al.
BREAST CANCER RESEARCH (2019)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2018)
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
Mette S. van Ramshorst et al.
LANCET ONCOLOGY (2018)
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
Xin Li et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET
Nadia Harbeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U. A. Nitz et al.
ANNALS OF ONCOLOGY (2017)
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
G. Bianchini et al.
ANNALS OF ONCOLOGY (2015)
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials
Emilio Bria et al.
CANCER TREATMENT REVIEWS (2014)
Comparative Effectiveness of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis
Aiko Nagayama et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET ONCOLOGY (2014)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A. Schneeweiss et al.
ANNALS OF ONCOLOGY (2013)
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
Andre Robidoux et al.
LANCET ONCOLOGY (2013)
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
Valentina Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
G. Valabrega et al.
ANNALS OF ONCOLOGY (2007)
分享论文
